ClinicalTrials.gg
CompletedNCT06354127Updated Apr 9, 2024

DWP450 for Treating Moderate to Severe Glabellar Lines

A Phase 3 interventional study of DWP450 and Botox® in Moderate to Severe Glabellar Lines, sponsored by Daewoong Pharmaceutical Co. LTD.. Completed at 1 site in China. Open to participants aged 20 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-04-09.

Sponsored by Daewoong Pharmaceutical Co. LTD. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 3 years 7 months after the study started (first participant enrolled Aug 2020, registered Apr 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
473
Allocation
Randomized
Ages
20 Years to 65 Years
Sex
All
01

Study summary

A multi-center, randomized, double-blind, positive drug-controlled clinical study to evaluate the safety and efficacy of Botulinum Toxin Type A for Injection in the treatment of moderate to severe glabellar lines

02

Conditions studied

  • Moderate to Severe Glabellar Lines
03

In context

Lead sponsor

Daewoong Pharmaceutical Co. LTD. is the lead sponsor of 200 studies on the registry; 33 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult males or females aged 20-65 years old.
  • Moderate to severe (grade 2-3) glabellar lines based on investigator's assessment of severity of glabellar lines at maximum frown.

Exclusion criteria

Exclusion Criteria:

  • Having received any glabellar (including forehead) cosmetic procedures/surgeries, such as dermal filling, face lifting, photoelectric therapy, hydro lifting, microneedle, chemical peeling or scar removal surgery, or dermabrasion within 6 months prior to screening.
  • Planning to receive any facial cosmetic procedures/surgeries, including but not limited dermal filling, face lifting, photoelectric therapy, hydro lifting, microneedle, chemical peeling or scar removal surgery, during the study period.
  • Skin infection at injection site or systemic skin disease assessed with the potential to interfere with efficacy evaluation or safety evaluation of glabellar lines or forehead lines.
  • Glabellar lines that cannot be fully flattened through surgery, by hand or by other methods.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
473 participants (actual)

Study arms

  • Experimental
    DWP450

    Drug: DWP450

  • Active comparator
    Botox®

    Drug: Botox®

Interventions

  • DrugDWP450

    The test drug or control drug is injected on the day of administration.

  • The test drug or control drug is injected on the day of administration.

06

What researchers measure

Primary outcomes

  1. Response rate based on the investigator's on-site assessment of severity of glabellar lines at maximum frown

    The difference between the two groups in response rate at Week 4 based on the investigator's on-site assessment of severity of glabellar lines (at maximum frown).

    Time frame: Week 4

07

Study locations

1 site
  • Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine
    Shanghai, Shanghai, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2020 to primary completion in Nov 2020, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 3, 2024
First posted
Apr 9, 2024
StartActual
Aug 12, 2020
Primary completionActual
Nov 24, 2020
CompletionActual
Jan 25, 2021
Last update
Apr 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06354127
Responsible party
Sponsor
First posted
Apr 9, 2024
Start date
Aug 12, 2020
Primary completion
Nov 24, 2020
Completion
Jan 25, 2021
Last update
Apr 9, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Prabotulinumtoxin A

Start the discussion